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ABSTRACT: Trefoil factor 3 (TFF3), cholinesterase activity (ChE activity) and homocysteine (Hcy) play critical 
roles in modulating recognition, learning and memory in neurodegenerative diseases, such as 
Parkinson's disease dementia (PDD) and vascular parkinsonism with dementia (VPD). However, whether they 
can be used as reliable predictors to evaluate the severity and progression of PDD and VPD remains largely 
unknown. Methods: We performed a cross-sectional study that included 92 patients with PDD, 82 patients with 
VPD and 80 healthy controls. Serum levels of TFF3, ChE activity and Hcy were measured. Several scales were 
used to rate the severity of PDD and VPD. Receivers operating characteristic (ROC) curves were   applied to map 
the diagnostic accuracy of PDD and VPD patients compared to healthy subjects. Results: Compared with healthy 
subjects, the serum levels of TFF3 and ChE activity were lower, while Hcy was higher in the PDD and VPD 
patients. These findings were especially prominent in male patients. The three biomarkers displayed differences 
between PDD and VPD sub-groups based on genders and UPDRS (III) scores’ distribution. Interestingly, these 
increased serum Hcy levels were significantly and inversely correlated with decreased TFF3/ChE activity levels. 
There were significant correlations between TFF3/ChE activity/Hcy levels and PDD/VPD severities, including 
motor dysfunction, declining cognition and mood/gastrointestinal symptoms. Additionally, ROC curves for the 
combination of TFF3, ChE activity and Hcy showed potential diagnostic value in discriminating PDD and VPD 
patients from healthy controls. Conclusions: Our findings suggest that serum TFF3, ChE activity and Hcy levels 
may underlie the pathophysiological mechanisms of PDD and VPD. As the race to find biomarkers or predictors 
for these diseases intensifies, a better understanding of the roles of TFF3, ChE activity and Hcy may yield insights 
into the pathogenesis of PDD and VPD.   
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Parkinson’s disease (PD) and vascular parkinsonism (VP) are among the most common neurodegenerative disorders. 
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Longitudinal studies have shown that many PD patients 
will eventually develop into PD with dementia (PDD), 
leading to poorer activities of daily living and increased 
caregiver burden [1, 2]. Although patients with VP show 
different neuro-pathogenesis than patients with PD, they 
typically present with similar clinical characteristics as 
PD [3]. For instance, in the later stages, both diseases 
present severe non-motor dysfunction, including impaired 
cognition and depression [4-6]. Compared with patients 
with PD or healthy controls, VP patients display more 
profound cognitive declines with impaired attention [7]. 
However, risk factors and time to onset for PDD and VP 
dementia (VPD) vary from patient to patient, reflecting 
the inter-individual heterogeneity underlying the different 
pathological substrates of PDD and VPD [3, 8]. Although 
these risk factors of ongoing PDD and VPD have not been 
clearly defined, several clinical predictors have been 
suggested. One population-based cohort study indicated 
that low CSF levels of -amyloid 42 (A42) at PD 
diagnosis predict substantial increased risk of early 
progression to dementia in patients with incident PD [9]. 
Several lines of evidence have also indicated that uric acid 
(UA) is a major natural antioxidant that might have 
neuroprotective properties [10, 11]. Low serum UA levels 
have been associated with worse cognitive functioning 
later in life and also with higher risk and faster 




Table 1. Demographic, motor, and non-motor parameters. 
 
Clinical parameters 
PDD   





VPD   







Max Mean (SD) Min Max 
Gender (n) Male n (%) 49(53.3) / / 44(55) / / 45(54.8) / / 
 Female n (%) 43(46.7) / / 36(45) / / 37(45.2) / / 
Age (years)  65.73(11.18) 56 88 64.43(7.10) 50 82 70.29(9.87) 65 83 
H&Y  2.85(1.23) 1 5 / / / 2.68(1.05) 1 5 
MMSE  21.72(3.94) 6 24 / / / 17.34(5.04) 1 23 
UPDRS  50.92(23.13) 17 96 / / / 44.36(19.03) 16 83 
 UPRDRS(I) 3.70(2.05) 1 12 / / / 3.79(3.08) 0 14 
 UPRDRS(II) 18.17(9.64) 3 45 / / / 16.57(8.79) 3 40 
 UPRDRS(III) 27.02(11.04) 9 51 / / / 22.49(9.58) 5 51 
 UPRDRS(Ⅵ) 2.03(2.50) 0 9 / / / 1.52(1.81) 0 7 
NMSS (total)  86.77(53.47) 20 188 / / / 103.22(44.42) 30 235 
 Cardiovascular 4.06 (2.90) 0 12 / / / 4.96(3.95) 0 18 
 Sleep/Fatigue 17.50(9.58) 0 36 / / / 19.64(8.90) 2 46 
 Mood 19.30(14.41) 3 54 / / / 23.30(12.51) 0 56 
 Perceptual problem 2.87(4.48) 0 18 / / / 3.47(5.92) 0 26 
 Attention/memory 11.27(7.79) 0 30 / / / 14.51(7.11) 0 30 
 Gastrointestina 9.35(6.54) 0 28 / / / 10.15(7.37) 0 31 
 Urinar 8.30(8.16) 0 32 / / / 11.18(7.93) 0 36 
 Sexual function 5.45(6.23) 0 18 / / / 8.41(7.69) 0 24 
 Miscellaneous 8.67(10.25) 0 36 / / / 7.61(7.20) 0 38 
Daily dose of 
L-Dopa (mg) 
 252.6(58.52) 206.44 291.14 / / / 275.06(65.77) 223.35 305.21 
Disease 
Duration 
 4.05(3.40) 0.5 15 / / / 3.53(3.36) 0.5 11 
 
SD, standard deviation; UPDRS, Unified Parkinson’s disease rating scale; H&Y, the modified Hoehn and Yahr staging scale; MMSE, mini-mental state 
examination and NMSS, non-motor symptoms scale for Parkinson’s disease. 
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Trefoil factor 3 (TFF3) is a neuropeptide secreted by 
secretory epithelial cells principally in the gastrointestinal 
tract and different cerebral regions including the 
hypothalamus, pituitary, hippocampi, temporal cortices 
and cerebellum [13-15]. Recent studies have shown that 
TFF3 may facilitate learning, objective recognition and 
retention of memory [16]. Low TFF3 in CSF is a 
predictive factor for brain atrophy and its potential role in 
the pathogenesis of Alzheimer disease (AD) has been 
suggested [17]. Multiple lines of evidence indicate that 
TFF3 is associated with vascular epithelial restitution [18] 
and anti-inflammatory effects and that it exerts protective 
effects against age-related diseases [17, 19]. 
Homocysteine (Hcy), a sulfur-containing amino acid 
produced by the interaction of cysteine and methionine, is 
closely related to cognitive impairment [20-23] and high 
levels can damage endothelial cells [24]. Although both 
TFF3 and Hcy are correlated with endothelial cell 
efficiency and declining cognition, the association of 
TFF3/Hcy levels with the severity of dementia in PD and 
VP has not been systemically evaluated.  
Cholinesterase activity (ChE activity), including 
acetylcholinesterase (AChE) activity and butyryl-
cholinesterase (BuChE) activity, has been studied as a 
marker for AD and plays a crucial role in preserving 
cognitive function [25, 26]. Previous studies have found 
that ChE activity levels reflect metabolic alterations 
associated with dementia, but they have not yielded 
information for their differential diagnoses [27, 28]. 
Several lines of evidence suggest that ChE/AChE 
activities contribute to regulating vascular endothelial 
dysfunction [29], suppressing inflammation and 
improving recovery prospects in cerebral ischemic 
diseases [30].  
TFF3, Hcy and ChE activity modulate cognitive 
function and are   associated with vascular function, 
inflammation and oxidative stress [17, 20, 24, 26, 29]. 
Vascular damage and chronic inflammation are observed 
in PDD and VPD patients [31-34]. Therefore, it is 
promising to investigate their levels and roles in PDD and 
VPD. The primary aim of this study was to compare 
serum levels of TFF3/ChE activity/Hcy among healthy 
subjects and patients with PDD and VPD. The secondary 
aim was to evaluate whether serum levels of TFF3/ChE 
activity/Hcy are associated with motor/non-motor 
dysfunctions in PDD and VPD. Lastly, we intended to 
determine the diagnostic value of serum levels of 
TFF3/ChE activity/Hcy in patients with PDD and VPD. 
Our study will provide a better understanding of the roles 
of TFF3, ChE activity and Hcy in the pathogenesis of 
PDD and VPD.  
 
MATERILAS AND METHODS 
 
Patients and Ethics Statement 
 
This cross-sectional study was performed in the 
Department of Neurology of the Third Affiliated Hospital 
of Sun Yat-sen University, Guangzhou, P. R. China. From 
November 2013 to October 2016, a total of 174 dementia 
patients (PDD and VPD patients) were recruited into this 
study. A total of 92 PD patients with dementia (49 males 
and 43 females, Table 1) were enrolled in this study. 
Diagnosis of PDD patients was carried out consensually 
between 2 clinicians using the diagnostic criteria for PDD 
[35]. An additional 82 VPD patients with dementia (45 
males and 37 females, Table 1) were recruited based upon 
the consensus criteria for the clinical diagnosis of VP. 
MMSE scores in all patients were less than 25. A total of 
80 healthy subjects (44 males and 36 females, Table 1) 
were recruited from the outpatient setting as the control 
group. All the outpatients were recruited from the Medical 
Examination Centre in the Third Affiliated Hospital of 
Sun Yat-sen University. Exclusion criteria for the study 
included hypertension, cerebral ischemia, cardiovascular 
disease, diabetes, renal dysfunction diabetes or 
psychiatric diseases (e.g. depression, drug addiction). 
Patients were also excluded if they presented with 
abnormal prostate carcinoma-related mediators, including 
prostate-specific antigen (PSA), carcinoembryonic 
antigen (CEA) or alpha-fetoprotein (AFP).   
This study was approved by the local Ethics 
Committee of the Third Affiliated Hospital of Sun Yat-sen 
University and was conducted in accordance with the 
principles outlined in the Declaration of Helsinki and the 
National Institutes of Health Human Subjects Policies and 
Guidance released on January and December 23, 1999, 
respectively. All participants provided written consent for 
the investigation and their consent to measure levels of 
serum TFF3, ChE activity and Hcy. Patients with PDD 
and VPD also completed additional disease-specific 
standard assessments, which were all conducted in a 




Experienced neurologists were recruited to perform the 
evaluations and completed the neurological examinations 
for both the treatment and control participants. All 
patients with PDD included in this study satisfied the 
criteria presented in Emre’s reports [35]. PDD exclusion 
criteria were as follows: (1) PDD patients with disability 
due to neurological disorders other than PDD, such as 
cerebrovascular disease, sequelae or psychosis; (2) PDD 
patients with somatic diseases that could have a potential 
effect on NMS (e.g., pain syndromes, advanced diabetes 
mellitus, malignancy, renal, hepatic/heart failure, severe 
anemia, any other acute/chronic debilitating or life-
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threatening diseases/states); (3) MMSE scores higher than 
25 (25 excluded); or (4) refusal to provide informed 
consent. All patients with VPD in this study fulfilled the 
criteria presented in Dunet and Zijlmans’ reports [31, 36] 
as follows: (1) parkinsonism, defined as bradykinesia and 
at least one of the following: resting tremor, rigidity or 
postural instability; (2) cerebrovascular disease, defined 
as evidence of relevant cerebrovascular disease by brain 
imaging or the presence of focal signs or symptoms that 
are consistent with stroke; (3) a relationship between these 
first two criteria and the following: an acute or delayed 
progressive onset of parkinsonism (within 1 year) after 
stroke with evidence of infarcts in or near areas that 
increase the basal ganglion motor output or decrease the 
thalamocortical drive directly OR an insidious onset of 
parkinsonism with extensive subcortical white matter 
lesions, bilateral symptoms at the onset and the presence 
of early shuffling gait or early cognitive dysfunction. All 
subjects completed the following battery of standard 
assessment measures: a standard demography form, the 
unified Parkinson’s disease rating scale (UPDRS) [37] 
and the modified Hoehn and Yahr staging scale (H&Y) 
[38]. The UPDRS(I) ‘mentation’ and UPDRS(II) ‘daily 
life’ subscales were used to evaluate psychiatric 
dysfunction and disease severity. The UPDRS (III) ‘motor’ 
and H&Y subscales were used to evaluate motor 
dysfunction and disease severity. The degree of non-
motor symptoms (NMS) in every patient was measured 
by the NMS scale (NMSS) [5, 39, 40]. Cognitive abilities 
were evaluated with the Mini-Mental State Examination 
(MMSE) [5, 41]. All scales were available and validated 
for the Chinese population [5]. According to Reinoso and 
Oosterveld’s studies, we divided the PDD and VPD into 
three sub-groups with UPDRS-III scores respectively, 
namely mild (≤30 points, 28 cases for PDD, 21 cases for 
VPD) , moderate ( 31-50 points, 39 cases for PDD, 36 
cases for VPD) and severe ( >50 points, 25 cases for PDD, 
25 cases for VPD) [42, 43]. All participants were scanned 
using magnetic resonance imaging (MRI) and 
representative MRIs for normal controls/PDD/VPD 
patients are shown in Figure 3. Demographic and clinical 
data for participants are shown in Table 1.  
  
Blood sampling measurement 
 
Venous blood samples for TFF3, ChE activity and Hcy 
measurements were obtained from all subjects in the study. 
5 ml of blood was drawn from the patients under fasting 
state in the morning and all of blood measurements were 
replicated thrice. The serum was separated for a total of 
1 h by centrifugation at 3,000 rpm for 10 min. Separated 
sera were stored at –30°C until laboratory evaluation took 
place. Serum levels of TFF3 were measured using 
commercial ELISA kits purchased from R&D Systems 
(Minneapolis, MN, USA) and performed in accordance 
with the manufacturer’s instructions. ChE activity levels 
were measured using the method of Ellman et al. [44]. 
Serum levels of Hcy were determined using a solid-phase 




Table 2. Comparison of age, MMSE, TFF3, Hcy and ChE activity among PDD, VPD and normal healthy subjects. 
 
 
Variable PDD VPD Control t Value p Value 
Tukey’s 
PDD/VPD PDD/Control VPD/Control 
Age 65.73±11.18 70.29±9.87 64.43±7.10 2.925 0.008** 0.007** 0.295 0.005** 
MMSE 21.72±3.94 17.34±5.04 30 3.523 0.001** 0.008** 0.000*** 0.000*** 
TFF3 15.21±11.83 14.03±12.25 18.20±6.21 -2.668 0.006* 0.089 0.007** 0.005** 
ChE 
activity 
7528±1573 7232±1254 7785±1962 -1.815 0.042* 0.882 0.067 0.028* 
Hcy 16.18±4.96 18.21±5.72 10.45±3.19 3.478  0.002** 0.625 0.008** 0.006** 
*p<0.05, **p<0.01, ***p<0.001.  Kruskal-Wallis test for the comparison among PDD, VPD and normal subjects, Tukey’s post hoc analysis 




All continuous variables, including age, UPDRS 
(UPDRS-I, -II, -III and -IV), MMSE, NMSS, TFF3, ChE 
activity and Hcy, are presented as their means ± SD. All 
categorical variables, including gender, are presented as 
percentages. Total scores for age, UPDRS, MMSE, 
NMSS, CRP, TFF3, ChE activity and Hcy were counted 
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by summing the single items. The statistical significance 
of differences between the groups was assessed by Mann–
Whitney U test and Kruskal–Wallis test when the data 
were not normally distributed; Student’s t-test was used 
when the data were normally distributed. One-way 
analysis of variance (One-way ANOVA) followed by 
Tukey’s post-hoc analysis was conducted to compare 
differences in TFF3/ChE activity/Hcy among normal 
subjects and PDD and VPD patients, including PDD and 
VPD sub-groups based on UPDRS(III) scores distribution. 
Spearman’s rank correlation coefficients (rs) were 
obtained to evaluate correlations among different clinical 
parameters. A receiver operating characteristic (ROC) 
analysis was conducted to assess the performance of 
clinical biomarkers (TFF3, ChE activity and Hcy) as 
diagnostic criteria for these diseases. Additionally, ROC 
curves for the combination of TFF3, ChE activity and Hcy 
were calculated as a possible better prognostic tool using 
logistic regression analysis. P-values <0.05 were deemed 
statistically significant and SPSS 13.0 (Chicago, IL, USA) 
was used for all statistical analyses.  
 
 
Table 3. Comparison of TFF3, Hcy and ChE activity between normal subjects and PDD patients according to genders. 
 
 
Variable  PDD (mean ± SD) Control (mean ± SD) 
PDD vs. Control PDD(Male) vs. (Female) 
Value p Value p 
TFF3 Male 15.03±11.26 20.12±9.51 -2.558  0.009**b 
 -2.976      0.003**a 
 Female 17.29±10.17  20.43±7.10 -2.911  0.006**a 
ChE activity Male 7596±1433 7736±1648 -2.083 0.038*a 
 -0.863      0.520b 
 Female 7680±1259 7839±1542 -1.915  0.026*b 
Hcy Male 18.21±4.72 11.39±2.80 3.974 0.000***b 
 3.239      0.003*a 
 Female 14.59±5.73 10.74±2.25 3.015  0.002*a 
*p<0.05, **p<0.01, ***p<0.001. a Mann-Whitney U-test. b Student’s t-test. 
 
RESULTS  
Patient Characteristics  
This cross-sectional study consisted of 92 PDD patients, 
82 VPD patients and 80 healthy subjects (Table 1). The 
mean age of the VPD patients was higher than the mean 
age of the PDD patients (Table 2) and the mean age of the 
VPD patients was higher than the mean age of the normal 
subjects (Table 2). There were no significant differences 
in ages among the PDD patients and the healthy controls 
(Table 2). Demographic and clinical data for all subjects 
are shown in Table 1. 
 
Comparisons of Age, MMSE, TFF3, ChE activity and 
Hcy between PDD/VPD Patients and Healthy Subjects 
 
In this study, the mean age for patients with VPD was 
higher than that of the PDD patients (Table 2) and the 
MMSE for patients with VPD was lower than that of PDD 
patients (Table 2). Significant differences in serum levels 
of TFF3/ChE activity/Hcy were found among the PDD 
and VPD patients and the control subjects (Table 2). 
Serum levels of TFF3 in PDD/VPD patients were lower 
than in normal subjects (Table 2), while no significant 
differences in TFF3 levels between PDD and VPD 
patients were observed. Similarly, ChE activity levels in 
patients with VPD were significantly lower than in the 
healthy subjects (Table 2). Serum Hcy levels in PDD/VPD 
patients were higher than in the normal subjects (Table 2), 
but no significant differences in Hcy levels between PDD 
and VPD patients were found.  
When PDD and VPD patients and normal subjects 
were divided into specific gender groups, the serum levels 
of TFF3 in the male/female patients with PDD were lower 
than those of the normal male/female subjects (Table 3). 
Similarly, a significant decrease was observed in plasma 
ChE activity between PDD male/female patients and 
normal male/female subjects (Table 3). However, a 
significant difference was observed in plasma Hcy levels 
between PDD male/female patients and normal 
male/female subjects (Table 3). Additionally, in PDD 
patients, levels of TFF3 in male patients were lower than 
in female patients (Table 3), while serum Hcy levels in 
male patients were higher than those in female patients 
with PDD (Table 3). There were no significant differences 
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in serum ChE activity levels between male PDD patients 
and female PDD patients (Table 3). Interestingly, our data 
showed that serum TFF3 and ChE activity levels in 
male/female VPD patients were significantly lower than 
in male/female normal subjects (Table 4), while Hcy 
serum levels were significantly higher than in 
male/female normal subjects (Table 4). TFF3 levels in 
male VPD patients were lower than in the female VPD 
patients (Table 4), while serum Hcy levels in male VPD 
patients were higher than those in female VPD patients 
(Table 4). There were no significant differences in the 
serum ChE activity levels between male VPD patients and 
female VPD patients. 
 
 
Table 4. Comparison of TFF3, Hcy and ChE activity between healthy subjects and VPD patients according to genders. 
 
 
Variable  VPD (mean ± SD) Control (mean ± SD) 
VPD vs. Control 
VPD(Male) vs. 
(Female) 
Value p Value p 
TFF3 Male 14.67±11.51 20.12±9.51 -3.956 0.000*a 
 -3.241     
 
0.004**a  Female 16.98±12.36 20.43±7.10 -3.579 0.002*b 
ChE activity Male 7286±1626 7736±1648 -2.066 0.032*b 
 -0.571     0.739b 
 Female 7351±1820 7839±1542 -2.017 0.041*a 
Hcy Male 21.11±5.24 11.39±2.80 3.923 0.000***a 
 2.939     0.003**b 
 Female 16.27±4.19 10.74±2.25 3.381 0.000***b 
*p<0.05, **p<0.01, ***p<0.001. a Mann–Whitney U-test. b Student’s t-test. 
 
Comparison of TFF3, Hcy and ChE activity between 
PDD and VPD patients according to genders and 
UPDRS-III scores  
 
We found serum Hcy levels in male VPD patients were 
significantly higher than those in male PDD patients 
(Table 5), while serum TFF3 and ChE activity didn’t 
display such gender-associated differences between PDD 
and VPD patients (Table 5). When PDD and VPD groups 
were divided into three sub-groups based on UPDRS-III 
scores respectively, we found serum TFF3 levels were 
significantly lower in VPD patients than those in PDD 
patients in UPDRS(III)≤30 and 31<UPDRS(III)<50 sub-
groups. Besides, our data showed that serum ChE activity 
were significantly lower in VPD patients than those in 
PDD patients in 31<UPDRS(III)<50 and UPDRS(III)>50 
sub-groups (Table 5).  
 
Correlation analyses among TFF3/ChE activity and 
Hcy Levels in PDD and VPD Patients 
 
To evaluate the relationships between TFF3/ChE activity 
and Hcy Levels in PDD and VPD patients, we conducted 
Spearman’s correlation analysis. We found a significant 
negative correlation between TFF3 and Hcy Levels in 
PDD and VPD patients (Table 6, Fig. 1). Similarly, a 
profound inverse correlation between ChE activity and 
Hcy levels was observed in PDD and VPD patients (Table 
6, Fig. 1).  
 
Correlations among TFF3/ChE activity/Hcy levels and 
age, UPDRS, H&Y, MMSE and NMSS (total/domain) in 
PDD and VPD Patients 
 
To evaluate correlations between the severity of the 
disease and clinical variables in PDD and VPD patients, 
we conducted Spearman’s correlation analysis among 
mediator variables and various assessments. We found 
TFF3 level was negatively correlated with UPDRS, 
UPDRS(Ⅲ) and H&Y staging and positively correlated 
with MMSE scores in PDD and VPD patients (Table 7). 
Although no significant correlations were observed for 
TFF3 and UPDRS(I), TFF3 and UPDRS(II), TFF3 and 
UPDRS(IV) or TFF3 and some of burdens of NMSS, 
there were significant correlations between TFF3 and 
NMS burdens of mood, attention/memory, as well as 
gastrointestinal distress in PDD and VPD patients (Table 
7).  
Besides, serum Hcy was positively correlated with 
H&Y staging and negatively correlated with MMSE 
scores in PDD and VPD patients (Table 7). Specifically, 
positive correlations were observed between Hcy and 
NMSS-cardiovascular burden in PDD and VPD patients, 
and between Hcy and NMSS-attention/memory burden in 
VPD patients (Table 7). There were, however, no 
significant correlations between Hcy and UPDRS, Hcy 
and UPDRS(I), Hcy and UPDRS(II), Hcy and 
UPDRS(Ⅲ), Hcy and UPDRS(IV) or Hcy and NMSS in 
either PDD/VPD patients.  
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Figure 1. Correlation analysis between TFF3/ChE activity and Hcy Levels in PDD and VPD patients. A significant negative 
correlation between (A) TFF3 and Hcy Levels in PDD patients (rs =-0.799, ***p<0.001); (B) ChE activity and Hcy Levels in PDD 
patients (rs =-0.732, ***p<0.001). (C) TFF3 and Hcy Levels in VPD patients (rs =-0.771, ***p<0.001). (D) ChE activity and Hcy 
Levels in VPD patients (rs =-0.713, ***p<0.001). 
Additionally, we found serum ChE activity was 
negatively correlated with UPDRS, UPDRS(Ⅲ), H&Y 
staging and positively correlated with MMSE scores in 
PDD and VPD patients (Table 7). There were negative 
correlations between ChE activity and the NMSS-
cardiovascular burden in VPD patients, and between ChE 
activity and NMS burdens of mood and attention/memory 
in PDD and VPD patients (Table 7). No significant 
correlations were observed between ChE activity and 
UPDRS (I/II/IV), ChE activity and NMSS in PDD and 
VPD patients. Interestingly, our results also showed that, 
although patients with PDD and VPD were treated with 
L-dopa, this L-dopa treatment was not significantly 
correlated to their serum levels of TFF3, Hcy or ChE 
activity (Table 7). This finding strongly suggests that L-
dopa medication in PDD and VPD patients does not 
influence the validity of TFF3/Hcy/ChE activity 
assessment in those PDD and VPD patients.   
ROC Curves for TFF3, ChE activity and Hcy in the 
Diagnosis of PDD and VPD  
 
ROC curves were constructed to explore whether TFF3, 
ChE activity and Hcy levels could provide credible 
discrimination between PDD patients and normal subjects. 
ROC curves for TFF3 analysis revealed that an area under 
the curve (AUC) value of 0.778 (Fig. 2A) was appropriate; 
the cut off was at 15.39 μmol/L, with a sensitivity of 62% 
and specificity of 90%. The AUC for Hcy was 0.690 (Fig. 
2C); the cut off was at 16.82 μmol/L, with a sensitivity of 
54% and specificity of 86%. However, the AUC for ChE 
activity was 0.516 (Fig. 2B), indicating no significant 
differences. The AUC for the combination of TFF3, Hcy 
and ChE activity was 0.880 (Fig. 2D), with a sensitivity 
of 68% and a specificity of 89% at a cutoff of 0.59 on the 
predicted risk algorithm. 
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     PDD 
Mean ± SD 
     VPD          
Mean ± SD 
PDD vs. VPD 
        Value                        p 
TFF3      
  Gender Male 15.03±11.26 14.67±11.51 0.153 0.8786 
 Female 17.29±10.17 16.98±12.36    0.902 0.123 
UPDRS(III) UPDRS(III)≤30 16.85±10.33 15.37±10.16 2.629 0.011a* 
 31<UPDRS(III)<50 15.74±10.29 14.16±10.03 3.140 0.003 a** 
 UPDRS(III)≤30 14.33±9.81 13.85±9.27 1.218 0.082 
ChE activity      
  Gender Male 7596±1433 7286±1626 0.982 0.3285 
 Female 7680±1259 7351±1820 0.951 0.345 
UPDRS(III) UPDRS(III)≤30 8027±1003 7829±1579 1.883 0.075 
 31<UPDRS(III)<50 7829±1282 7320±1050 2.145 0.037 a* 
 UPDRS(III)>50 7462±1291 7057±1331 2.335 0.020 a* 
Hcy      
  Gender Male 18.21±4.72 21.11±5.24 2.832 0.006b** 
 Female 14.59±5.73 16.27±4.19 1.476 0.144 
  UPDRS(III) UPDRS(III)≤30 17.82±3.94 19.33±4.91 0.232 0.713 
 31<UPDRS(III)<50 16.35±4.31 18.56±4.43 0.537 0.281 
 UPDRS(III)>50 15.78±4.60 17.41±3.89 0.891 0.371 
 
*p<0.05, **p<0.01, ***p<0.001. a Tukey’s post hoc analysis. b Mann-Whitney U-test. 
 
Furthermore, in VPD patients, the AUC for TFF3 
was 0.748 (Fig. 2E); the cut-off was at 14.21 µmol/L, with 
a sensitivity of 60% and a specificity of 75%. The AUC 
for Hcy was 0.623 (Fig. 2G); the cut off was at 18.36 
μmol/L, with a sensitivity of 48% and specificity of 66%. 
However, the AUC for ChE activity was 0.567 (Fig. 2F); 
the cut off was at 7250 U/L, with a sensitivity of 44% and 
specificity of 56%. The AUC for the combination of TFF3, 
Hcy and ChE activity was 0.846 (Fig. 2H), with a 
sensitivity of 57% and a specificity of 76% at a cutoff of 
0.53 on the predicted risk algorithm. These data indicate 
that the combination variable was more robust than TFF3, 
ChE activity or Hcy alone in distinguishing PDD and 
VPD patients from healthy controls.   
 
 
Figure 2. ROC curves to evaluate the 
utility of serum levels of TFF3, ChE 
activity and Hcy Levels for the 
discrimination of PDD/VPD patients from 
healthy controls. (A-D) The AUC of ROC 
curves for discrimination of PDD patients 
from healthy controls (A) TFF3, (B) ChE 
activity, and (C) Hcy were 0.778 (95%CI: 
0.706–0.850, *p=0.037), 0.516 (95%CI: 
0.423–0.609, p=0.737), and 0.690 (95%CI: 
0.606–0.774, *p=0.043), respectively. The 
AUC of (D) TFF3+ChE activity+Hcy was 
0.880 (95%CI: 0.828–0.932, *p=0.027). (E-
H) The AUC of ROC curves 
for discrimination of VPD patients from 
healthy controls. (E) TFF3, (F) ChE activity, 
and (G) Hcy were 0.748 (95%CI: 0.671–
0.826, *p=0.040), 0.567 (95%CI: 0.475–
0.660, *p=0.047), and 0.623 (95%CI: 0.533–
0.713, *p=0.046), respectively. The AUC 




We found several important results in this study. First, we 
found a pronounced decrease in the serum levels of TFF3 
and ChE activity and an increase in the levels of Hcy in 
PDD/VPD patients when compared to healthy subjects. 
Second, increased serum Hcy levels were significantly 
and inversely correlated with decreased TFF3/ChE 
Zhou J. et al                                                                                     TFF3 and ChE activity as markers for PDD and VPD   
Aging and Disease • Volume 9, Number 1, February 2018                                                                               59 
 
activity levels. Third, there were significant correlations 
between TFF3/ChE/Hcy levels and the severity of 
PDD/VPD, including motor dysfunction, declining 
cognition and mood/gastrointestinal symptoms. Lastly, 
our ROC curve analysis strongly indicated that the 
combination of TFF3, ChE activity and Hcy could 
significantly discriminate PDD/VPD patients from 
healthy subjects and could be applied as a potential 
screening instrument for disease diagnosis. To our 
knowledge, this is the first study to explore changes in the 
serum levels of TFF3 and ChE activity in PDD/VPD 
patients and to evaluate the potential relationships 
between TFF3 and the dementia. The interesting finding 
of inversed correlation between serum TFF3/ChE activity 
and Hcy levels may shed light on the underlying 






Figure 3. MRI images in normal controls and PDD and VPD patients.  (A) Normal subjects, (B) PDD patients, 
(C) VPD patients. The extent of white matter hyperintensities and multiple infarctions in the basal ganglia in the VPD 
patients are shown in T2-weighted and FLAIR images. Arrows indicate the infarction.  
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Table 6.  Spearman’s rank correlation coefficient (rs) and p-values between TFF3/ChE activity and Hcy 




Hcy in PDD Hcy in VPD 
r p r p 
TFF3      -0.799  0.000***   -0.771 0.000***   
ChE activity     -0.732 0.000***   -0.713 0.000***   
*p<0.05, **p<0.01, ***p<0.001. rs, Spearman’s rank correlation coefficient.  
 
Over the past few years, comparisons of VPD and 
PDD patients have received significant attention for the 
diagnosis, therapy and evaluation of their status [36, 45-
48]. We found that NMS (including cardiovascular, sleep 
and mood disorders) are very common in patients with 
PDD and VPD, with a prevalence of NMS in the group of 
100% and an NMSS for PDD (Table 1) consistent with 
previous reports [39, 49]. Interestingly, as shown in 
Tables 1 and 2, our patients with VPD exhibited shorter 
disease durations and older ages at onset than those 
patients with PDD. This finding implies that Chinese VPD 
patients may develop symptoms later in life, but they may 
experience deterioration faster than PDD patients. 
Additionally, a later age at onset of VP would favor a 
vascular cause [31]. Significant reductions in scores on 
the MMSE were observed in VPD patients when 
compared to the PDD group (Table 2). This result 
demonstrates that compared to PDD subjects, Chinese 
VPD patients had already undergone a greater decline in 
cognitive function by the time they visited the neurologist. 
This result is in agreement with Zijlmans’ finding [36] and 
implies that our VPD patients may have more subcortical 
lesions than the patients with PDD and these subcortical 
vascular ischemic lesions may have led to their more 
rapidly declining cognition [7].    
Until now, the roles of TFF3 in the central nervous 
system have not been adequately explored. TFF3 has been 
previously documented to be associated with cognitive 
functioning, including vascular epithelial restitution and 
suppressing inflammation in the central nervous system 
[16-19]. TFF3 levels in patients with PDD/VPD were 
significantly lower than in the healthy subjects, similar to 
findings from other neurodegenerative diseases such as 
AD [17]. When compared to healthy controls, these 
decreased TFF3 levels in PDD/VPD patients imply that 
TFF3 contributes to the pathophysiological mechanisms 
of disease development. Serum ChE activity reflects 
metabolic alterations associated with dementia [50]. 
Szilagyi et al. described lowered serum and CSF ChE 
activity in patients with dementia [51]. We also found that 
serum ChE activity in VPD patients was significantly 
lower than that in healthy subjects. Although serum ChE 
activity in PDD patients was lower than in healthy 
subjects, the difference did not reach significance. One 
possible explanation may be that these declines in ChE 
activity in the CNS are not low enough to affect peripheral 
concentrations in PDD patients [52]. It has been well 
documented that altered TFF3 and ChE activity are 
associated with a higher risk of AD. Low CSF TFF3 levels 
are associated with both the rate of cognitive decline and 
the rate of hippocampal atrophy and ventricular expansion 
[17]. Several lines of evidence have indicated that 
significantly lower cortical and thalamic AChE activity 
are associated with declines in cognitive impairment [52]. 
Therefore, in the diagnosis and evaluation of PDD and 
VPD, TFF3 and ChE activity could be used as potential 
markers.   
Previous studies have demonstrated that elevated 
plasma Hcy levels represent a risk factor for declining 
cognition and dementia in the general population [22, 53], 
but Hcy levels have also been associated with mild 
cognitive impairment (MCI), AD, PD, and vascular 
dementia [20, 23, 54, 55]. Similar results have been 
observed in PDD and VPD patients. These findings 
strongly suggest that higher levels of Hcy may contribute 
to the severity of PDD and VPD. Therefore, Hcy may be 
a possible target in the treatment of PDD and VPD [54, 
56].  
After dividing subjects by gender, we noticed (Table 
4) that serum TFF3 levels in male PDD/VPD patients 
were significantly lower than female PDD/VPD patients, 
while serum Hcy levels in male PDD/VPD patients were 
significantly higher than in female PDD/VPD patients. 
This finding suggests that serum TFF3 and Hcy may be 
more useful in evaluating PDD/VPD in men. These bio-
physiological associations between gender-specific 
hormones and TFF3/Hcy may be partly attributable to 
higher occurrences of PDD/VPD in men [57, 58].  
Interestingly, we observed no significant difference 
in serum TFF3, ChE activity and Hcy levels between PDD 
and VPD patients. This finding may be due to the similar 
neuro-pathogenesis between PDD and VPD, i.e. those 
three factors participating the vascular epithelial 
restitution and suppressing inflammation in the brain [18, 
19, 22, 26, 29]. We next explored the differences between 
PDD and VPD patients. Although the three serum 
Zhou J. et al                                                                                     TFF3 and ChE activity as markers for PDD and VPD   
Aging and Disease • Volume 9, Number 1, February 2018                                                                               61 
 
biomarkers displayed no difference between these two 
groups, serum Hcy levels were higher in male VPD 
patients than those in male PDD patients (Table 5), 
implying Hcy may be more suitable to evaluate the status 
and more closely correlated to the neuro-pathogenesis in 
male VPD patients [58]. When PDD and VPD groups 
were divided into three sub-groups based on UPDRS-III 
scores respectively, we found serum TFF3 levels were 
significantly lower in VPD patients than those in PDD 
patients in UPDRS(III)≤30 and 31<UPDRS(III)<50 sub-
groups. This finding suggests that in VPD patients, 
especially in the early-mid stage, micro-vascular 
impairment and inflammatory response are more 
prominent, as indicated by the lower levels of serum TFF3 
in VPD compared to PDD [4, 6, 18, 19]. Interestingly, we 
noticed that serum ChE activity was significantly lower in 
VPD patients than those in PDD patients in 
31<UPDRS(III)<50 and UPDRS(III)>50 sub-groups 
(Table 5). This result strongly implies that during mid-
later stage, cerebral function is more impaired and more 
neurons are damaged in VPD compared to PDD, as shown 
by lower ChE activity in VPD [25, 26]. Whether serum 
TFF3 and ChE activity could be used in evaluating the 
status of VPD and PDD needs further exploration.  
 
 
Table 7. Spearman’s rank correlation coefficient (rs) and p-values between clinical variables and H&Y, MMSE, 
NMSS(total/domain) s in PDD and VPD patients. 
 
 
Variable TFF3 (PDD) Hcy (PDD) 
ChE activity 
(PDD) 
TFF3 (VPD) Hcy  (VPD) 
ChE activity 
(VPD) 
 r p r p r p r p r p r p 
Age 0.423 0.091 0.138 0.550 0.168 0.433 0.474 0.087 0.257 0.375 0.134 0.647 
UPDRS -0.126** 0.007 0.134 0.053 -0.319* 0.019 -0.795** 0.001 0.193 0.195 -0.367* 0.015 
Up(Ⅰ) -0.096 0.521 0.169 0.256 -0.270 0.237 -0.133 0.535 0.030 0.220 -0.463 0.096 
Up(Ⅱ) -0.091 0.541 0.173 0.247 -0.134 0.367 -0.458 0.065 0.143 0.289 -0.197 0.355 
Up(Ⅲ) -0.327* 0.025 0.283 0.213 -0.397* 0.015 -0.578* 0.015 0.073 0.274 -0.298* 0.017 
Up(Ⅳ) -0.052 0.645 0.042 0.712 -0.037 0.742 -0.266 0.106 0.185 0.079 -0.037 0.745 
H&Y -0.315* 0.031 0.342* 0.019 -0.269* 0.025 -0.206* 0.047 0.306* 0.026 -0.379* 0.022 
MMSE 0.378** 0.009 -0.364* 0.012 0.358* 0.014 0.249* 0.026 -0.339* 0.030 0.418** 0.008 
NMSS 0.241 0.103 0.006 0.978 0.065 0.681 0.086 0.074 0.127 0.071 0.049 0.462 
Cardiovascular -0.205 0.168 0.359* 0.015 -0.201 0.178 -0.094 0.138 0.115* 0.014 -0.207* 0.048 
Sleep/Fatigue -0.478 0.084 0.417 0.064 -0.057 0.755 -0.026 0.616 0.085 0.218 -0.041 0.526 
Mood -0.351* 0.015 0.067 0.681 -0.391** 0.001 -0.343* 0.028 0.070 0.601 -0.393** 0.001 
Perceptual 
problem 
-0.058 0.218 0.080 0.253 –0.185 0.105 -0.074 0.646 0.054 0.392 –0.035 0.831 
Attention/ 
memory 
-0.118* 0.014 0.009 0.950 –0.249* 0.026 -0.243* 0.029 0.362* 0.013 -0.341* 0.034 
Gastrointestina -0.668** 0.009 -0.141 0.341 -0.069 0.645 -0.769** 0.001 0.113 0.103 -0.112 0.075 
Urinar -0.045 0.763 0.018 0.915 -0.021 0.894 -0.063 0.190 0.054 0.462 -0.205 0.198 
Sexual function -0.219 0.140 0.029 0.846 –0.227 0.164 -0.083 0.071 0.073 0.301 -0.250 0.115 
Miscellaneous -0.044 0.350 -0.007 0.919 –0.208 0.155 -0.410 0.081 0.230 0.119 -0.104 0.487 
Daily dose of L-
Dopa (mg) 
-0.071 0.130 0.131 0.058 -0.100 0.497 -0.031 0.502 0.027 0.695 -0.002 0.972 
*p<0.05, **p<0.01,***p<0.001. rs, Spearman’s rank correlation coefficient; UPDRS, Unified Parkinson’s disease rating scale; H&Y, the modified Hoehn 
and Yahr staging scale; MMSE, mini-mental state examination; NMSS, non-motor symptoms scale for Parkinson’s disease. 
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TFF3 and ChE activity showed strong negative 
correlations with UPDRS, H&Y and NMSS (mood and 
attention/memory) and positive correlations with MMSE 
in PDD/VPD patients. This finding strongly suggests that 
serum levels of TFF3 and ChE activity may significantly 
influence motor and non-motor dysfunction in PDD and 
VPD patients. Previous studies have indicated that TFF3 
deficiency presents with a significant forelimb motor 
dysfunction in experimental ischemic injury mice [59]. 
Significant correlations were also observed between 
decreased cortical AChE activity and higher total UPDRS 
scores in patients with PD [52, 60]. These findings 
suggested that the ascending cholinergic system from the 
nucleus basalis of Meynert to the cerebral cortex is 
impaired more severely as PD advances. We also found 
similar findings for ChE activity, with significant 
correlations between lower ChE activity and higher 
UPDRS/UPDRS III scores in PDD and VPD patients. 
Specifically, TFF3 and ChE activity showed negative 
associations with mood and attention/memory and 
positive correlations with MMSE in PDD/VPD patients, 
further demonstrating that these two dysfunctions could 
be important targets for disease evaluation using plasma 
levels of TFF3 and ChE activity. Consistent with our 
notions, several studies have shown that TFF3 deficiency 
and low levels of ChE activity are correlated with mood, 
memory deterioration and cognitive function [16, 50]. We 
also noticed plasma levels of TFF3 showed robust 
associations with the gastrointestinal domain in PDD and 
VPD patients, implying that TFF3 could be a high-risk 
factor for gastrointestinal disease. Interestingly, Hcy 
demonstrated strong positive correlations with H&Y and 
NMSS (cardiovascular domain) and a negative correlation 
with MMSE in PDD/VPD patients, implying that plasma 
Hcy levels might be used to evaluate the severity of 
cognitive status of PDD and VPD patients [61, 62].  
Since several lines of evidence show that TFF3, ChE 
and Hcy may be involved in the pathogenesis of dementia 
[16, 22, 23, 26], we specifically explored the relationships 
among serum TFF3, ChE and Hcy. In the current study, 
we noticed a significant and inverse correlation between 
Hcy and TFF3/ChE activity in PDD and VPD patients 
(Table 6, Figure 1). Previous studies have indicated that 
elevated plasma Hcy increases the risk of dementia by 
impacting cerebrovascular pathology [5, 6, 63, 64]. These 
higher levels of Hcy in PDD/VPD patients may damage 
neuron and vascular endothelial cells in the brain, 
inducing neuroinflammation [23, 65, 66]. High levels of 
Hcy could break down the blood brain barrier (BBB) and 
lead to cerebrovascular dysfunction, which subsequently 
modulates the activities of enzymes and neuropeptides 
and influences hippocampal volume in the 
pathophysiological processes of dementia [67-69]. It has 
been shown that Hcy could stimulate superoxide and 
hydrogen peroxide generation in vivo and in vitro [70] and 
that ChEs activities are inhibited by high level of Hcy 
mediated by the generation of free radical formation [71-
73]. Multiple lines of evidence indicate that TFF3 exerts 
protective effects via promoting vascular epithelial 
restitution and anti-inflammation，which is opposite to 
the effects of Hcy [17-19]. Therefore, we propose that 
Hcy may negatively influence cognitive functioning in 
PDD/VPD patients via altering cerebrovascular pathology 
and subsequently downregulating TFF3/ChE activity, 
subsequently leading to impaired cognition in PDD and 
VPD. Based on this finding, we hypothesize that the 
combination of TFF3, ChE activity and Hcy would be an 
early pathophysiological marker for cognitive 
dysfunction in VP and PD patients.  
Our ROC data indicate an acceptable sensitivity and 
specificity for TFF3 and ChE activity in the potential 
discrimination of PDD/VPD patients from normal 
subjects. Notably, TFF3 displays more reliable 
discrimination when compared to ChE activity (Figures 
2A, D). Moreover, one of the most notable findings in the 
current study showed that the combination of TFF3 and 
ChE activity and Hcy exhibited better discriminatory 
ability in PDD/VPD, in comparison to TFF3, ChE activity 
or Hcy alone. With the use of the serum TFF3 and ChE 
activity as screening tools, clinicians could potential use 
these as a combined biomarker to potentially detect 
PDD/VPD.           
There are several limitations to this study: (1) a small 
number of participants (92 PDD patients, 82 VPD patients, 
and 80 healthy subjects) were recruited. Therefore, it is 
necessary to conduct a large population study in the future; 
(2) most patients with PDD/VPD were at middle-late 
stages of the disease, with a high median stage on the 
H&Y scale and a relatively low MMSE score (21.72 for 
PDD patients, 17.34 for VPD patients); (3) our study is a 
cross-sectional study. Therefore, longitudinal cohort 
studies are needed in the future to explore the alterations 
of the three serum biomarkers (TFF3, ChE and Hcy) 
during the disease progression in PDD and VPD; (4) 
genetic factors such as the TFF3 genotype and folate or 
cholinesterase inhibitor administration were not 
considered in this study; (5) to validate and complete the 
questionnaire, we chose only PDD and VPD patients with 
sufficient cognitive ability, which significantly narrowed 
the study population. The above criteria (1–5) in the 
population chosen may have resulted in a bias for serum 
levels of TFF3, ChE activity and Hcy in PDD/VPD 
patients. Therefore, it is necessary to conduct a large 
population study in the future.  
In summary, the current study supports the notion 
that decreased serum TFF3/ChE activity and increased 
Hcy may be related to the pathophysiology of PDD and 
VPD. Based on this study, it is reasonable to speculate that 
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high levels of serum Hcy may negatively influence 
cognitive function in PDD/VPD patients through various 
mechanisms, including inducing cerebrovascular 
pathology and subsequent downregulation of TFF3/ChE 
activity. Furthermore, low levels of serum TFF3 and ChE 
activity combined with high levels of serum Hcy may 
predispose patients to the progressive stages in both motor 
and non-motor dysfunctions. Based on our findings, we 
propose that serum TFF3, ChE activity and Hcy may 
underlie the pathophysiological mechanisms of 
PDD/VPD and could be used to evaluate the severity of 
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